UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~February~~March 2018, 2019

Array BioPharma Inc.

(Exact name of registrant as specified in its charter)



Delaware	001-16633	84-1460811
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

3200 Walnut Street, Boulder, Colorado 80301

(Address of principal executive offices, including Zip Code)

303 381-6600

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:



¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

In this report, “Array BioPharma,” “Array,” “we,” “us” and “our” refer to Array BioPharma Inc., unless the context otherwise provides.

Item 57.0201 ~~Departure~~Regulation ofFD ~~Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers~~Disclosure.

On ~~February~~March 1918, 2019, ~~Curtis~~Array ~~Oltmans~~BioPharma ~~notified~~Inc. ~~Array~~issued a press release announcing that hethe ~~will~~National beComprehensive ~~resigning~~Cancer asNetwork© ~~Executive~~(NCCN©) ~~Vice~~has ~~President,~~updated ~~General~~the ~~Counsel~~Clinical Practice Guidelines in Oncology for Colon and ~~Secretary~~Rectal ofCancer ~~Array~~to ~~(“General~~include ~~Counsel”).~~BRAFTOVI® ~~Mr.~~in ~~Oltmans’s~~combination ~~last~~with ~~day~~MEKTOVI® ofand ~~employment~~cetuximab or panitumumab as a Category 2a treatment for patients with ~~Array~~BRAFV600E-mutant ~~will~~metastatic becolorectal ~~March~~cancer 19(mCRC), ~~2019.~~after ~~Mr.~~failure ~~Oltmans’s~~of ~~resignation~~one ~~did~~to ~~not~~two ~~arise~~prior ~~from~~lines ~~any~~of ~~disagreement~~therapy onfor ~~any~~metastatic ~~matter~~disease. A ~~relating~~copy of the press release is included as Exhibit 99.1 to ~~Array’s~~this ~~operations,~~Form ~~policies~~8-K orand ~~practices~~incorporated herein by reference.

~~Array’s~~Item ~~Board of Directors has appointed Rogan P~~9.01 ~~Nunn~~Financial asStatements ~~interim General Counsel effective February 19, 2019. Mr. Nunn will serve as Array’s interim General Counsel pursuant to an agreement with Skadden, Arps, Slate, Meagher & Flom LLP~~ and ~~Affiliates, where Mr~~Exhibits. Nunn is a Senior Associate specializing in corporate law, securities law, corporate governance, mergers and acquisitions and complex transactions. Previously, Mr. Nunn held positions at Morgan Stanley and KPMG, LLP. Mr. Nunn holds a Bachelor of Science in Finance and International Business from Georgetown University and a Juris Doctor from the University of Virginia School of Law.

(d) Exhibits



Exhibit No.		Description
99.1		Press release dated March 18, 2019.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: February 20, 2019	Array BioPharma Inc.
Date: March 18, 2019	Array BioPharma Inc.
	By:	/s/ JASON HADDOCK
		Jason Haddock
		Chief Financial Officer

Filing Compare · ARRAY BIOPHARMA INC